[1]马 峰,梁珊珊,万春晶,等.ABO血型不合异基因造血干细胞移植患者血型转变及其对造血重建的影响研究[J].现代检验医学杂志,2026,41(03):163-166.[doi:10.3969/j.issn.1671-7414.2026.03.029]
　MA Feng,LIANG Shanshan,WAN Chunjing,et al.Study on the Blood Group Conversion and Its Impact on Hematopoietic Reconstitution in Patients Undergoing ABO-Incompatible Allogeneic Hematopoietic Stem Cell Transplantation[J].Journal of Modern Laboratory Medicine,2026,41(03):163-166.[doi:10.3969/j.issn.1671-7414.2026.03.029]
点击复制

ABO血型不合异基因造血干细胞移植患者血型转变及其对造血重建的影响研究()

《现代检验医学杂志》[ISSN:/CN:]

卷:
第41卷
期数:
2026年03期
页码:
163-166
栏目:
论著
出版日期:
2026-05-13

文章信息/Info

Title:
Study on the Blood Group Conversion and Its Impact on Hematopoietic Reconstitution in Patients Undergoing ABO-Incompatible Allogeneic Hematopoietic Stem Cell Transplantation
文章编号:
1671-7414（2026）03-163-04
作者:
马 峰，梁珊珊，万春晶，王 娜，王宝燕
西安交通大学第一附属医院输血科，西安710061
Author(s):
MA Feng，LIANG Shanshan，WAN Chunjing，WANG Na，WANG Baoyan
Department of Blood Transfusion, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, China
关键词:
ABO血型不合; 异基因造血干细胞移植; 血型转变; 造血重建
分类号:
R457.7；R457.11
DOI:
10.3969/j.issn.1671-7414.2026.03.029
文献标志码:
A
摘要:
目的?探讨ABO血型不合异基因造血干细胞移植（allo-HSCT）患者血型转变及造血重建规律，为患者临床输血提供指导性依据。方法选取2019～2023年西安交通大学第一附属医院血液科ABO血型不合allo-HSCT患者37例，其中主要不合组11例、次要不合组17例、主次双向不合组9例，比较三组血型转变时间、造血重建时间以及造血重建周期内红细胞及血小板的输注量差异。结果血型完全转变时间主要不合组162（64，230）天、次要不合组106（63，150）天、主次双向不合组170（145，240）天。与次要不合组相比，主要不合组及主次双向不合组血型完全转变时间明显延长，差异具有统计学意义（Z=16.308、18.139，均P＜0.05），主要不合组与主次双向不合组相比差异无统计学意义（Z=0.406，P＞0.05）。三组血型初次转变时间、粒系重建时间、巨核系重建时间、红系重建时间、造血重建周期内红细胞及血小板输注量差异无统计学意义（Z=0.521～5.815，均P＞0.05）。结论ABO血型不合对allo-HSCT后血型转变存在明显影响，主要不合及主次双向不合患者ABO血型完全转变时间明显延长。
Abstract:
Objective To explore the patterns of blood group conversion and hematopoietic reconstruction in patients undergoing ABO-incompatible allogeneic hematopoietic stem cell transplantation (allo-HSCT), providing guidance for clinical blood transfu-sion management. Methods Thirty-seven patients who undergoing ABO-incompatible allo-HSCT at the Hematology Department of the First Affiliated Hospital of Xi’an Jiaotong University from 2019 to 2023 were enrolled, including 11 in the major ABO-in-compatible group, 17 in the minor ABO-incompatible group, and 9 in the bidirectionally ABO-incompatible group. Differences in time to blood group conversion and hematopoietic reconstruction, and red blood cell and platelet transfusion volumes during the hematopoietic reconstruction period were compared among the three groups. Results The time for complete blood group con-version after ABO-incompatible allogeneic HSCT was 162 (64, 230) days in the major ABO-incompatible group, 106 (63, 150) days in the minor ABO-incompatible group, and 170 (145, 240) days in the bidirectionally ABO-incompatible group. Compared with the minor ABO-incompatible group, the time for complete blood group conversion was significantly longer in the major and bidirectionally ABO-incompatible groups (Z=16.308, 18.139, all P<0.05), while there was no significant difference between the major and bidirectionally ABO-incompatible groups (Z=0.406, P>0.05). There were no significant differences in the time for ini-tial blood group conversion, granulocyte reconstruction time, megakaryocyte reconstruction time, erythroid reconstruction time, or RBC and platelet transfusion volumes during the hematopoietic reconstruction period among the three groups (Z=0.521~5.815, all P>0.05). Conclusions ABO incompatibility significantly affects blood group conversion after allo-HSCT, with a significantly prolonged time to complete blood group conversion in patients with major and bidirectionally ABO-incompatible allogeneic HSCT.

参考文献/References:

[1] CHEN Y, WAN X J, CAO Y, et al. ABO incompatibil-ity does not affect transfusion requirements or clinical outcomes of unrelated cord blood transplantation after myeloablative conditioning for haematological malig-nancies[J]. Blood Transfusion , 2022, 20(2): 156-167.
[2] 黄晓军. 实用造血干细胞移植[M].2版.北京:人民卫生出版社,2022:136-137. HUANG X J. Practice of hematopoietic stem cell trans-plantation[M]. 2nd ed. Beijing: People’s Health Pub-lishing House, 2022: 136-137.
[3] DAMODAR S, SHANLEY R, MACMILLAN M, et al. Donor-to-recipient ABO mismatch does not impact outcomes of allogeneic hematopoietic cell transplanta-tion regardless of graft source[J]. Biology of Blood and Marrow Transplantation, 2017, 23(5): 795-804.
[4] MIELCAREK M, LEISENRING W, TOROK-STORB B, et al. Graft-versus-host disease and donor-directed hemag-glutinin titers after ABO-mismatched related and unrelated marrow allografts: evidence for a graft-versus-plasma cell effect[J]. Blood, 2000, 96(3): 1150-1156.
[5] BOOTH G S, GEHRIE E A, BOLAN C D, et al. Clinical guide to ABO-incompatible allogeneic stem cell transplantation[J]. Biology of Blood and Marrow Transplantation, 2013, 19(8): 1152-1158.
[6] 汪德清. 输血技术操作规程(输血科部分)[M].北京:人民卫生出版社,2016:13-19. WANG D Q. Blood transfusion technical operating pro-cedures (transfusion department part) [M]. Beijing: Bei-jing People’s Health Publishing House, 2016: 13-19.
[7] FUNG M K, EDER A , SPITALNIK S L, et al. AABB Technical Manual [M].19th ed. Bethesda (MD): Ameri-can Association of Blood Banks, 2017:683-691.
[8] ABOi-HSCT血型检测与血液成分输注专家共识编写组. ABO血型不合异基因造血干细胞移植受者血型检测与血液成分输注专家共识[J].中国输血杂志, 2023,36(11):971-977 Writing Group of Expert Consensus on ABOi-HSCT Blood Group Testing and Transfusion. Expert consen-sus on recipient blood type test and blood component transfusion after ABO-incompatibility hematopoietic stem cell transplantation[J]. Chinese Journal of Blood Transfusion, 2023, 36(11): 971-977.
[9] 罗成岑,封彦楠,马春娅,等. ABO血型对异基因造血干细胞移植患者植入的影响探讨[J].中国输血杂志,2021,34(3):252-256. LUO C C, FENG Y N, MA C Y, et al. Exploring the impact of ABO blood group on the outcomes of allo-geneic hematopoietic cell transplantation [J]. Chinese Journal of Blood Transfusion, 2021, 34(3): 252-256.
[10] 余忠清,程汉华,陈凤花,等.异基因造血干细胞移植ABO转型特征与免疫相关性疾病的防治策略[J].中华临床医师杂志(电子版),2013,7(5):14-17. YU Z Q, CHENG H H, CHEN F H, et al. Characteris-tics of ABO transformation in allogeneic hematopoietic stem cell transplantation and prevention and treatment strategies for immune-related diseases[J]. Chinese Jour-nal of Clinicians(Electronic Edition), 2013, 7(5): 14-17.
[11] 异基因造血干细胞移植临床输血专家共识起草专家组. 异基因造血干细胞移植临床输血专家共识[J]. 临床输血与检验,2023,25(5):586-593. Expert Consensus on Clinical Blood Transfusion of Allogeneic Hematopoietic Stem Cell Transplantation Working Party. Expert consensus on blood transfusion of allogeneic hematopoieticstem cell transplantation [J]. Journal of Clinical Transfusion and Laboratory Medi-cine, 2023, 25(5): 586-593.
[12] 高雨菡,田文沁. ABO血型不合造血干细胞移植患者的血型格局变化及其输血策略[J].北京医学,2017, 39(6):637-640. GAO Y H, TIAN W Q. Changes in blood type pattern and transfusion strategies in ABO incompatible hema-topoietic stem cell transplantation patients[J]. Beijing Medical Journal, 2017, 39(6) :637-640.
[13] 蔡雪娇,陈碧乐,谢作听,等. ABO血型不合的异基因造血干细胞移植骨髓空虚期血型的血清学特性研究[J].中国实验血液学杂志,2016,24(1):221-224 CAI X J, CHEN B L, XIE Z T, et al. Study on sero-logical blood group conversion in BM empty phase of ABO-incompatible allogeneic stem cell transplantation [J]. Journal of Experimental Hematology, 2016, 24(1):221-224.
[14] LEE J H, LEE K H, KIM S, et al. Anti-a isoagglutinin as a risk factor for the development of pure red cell aplasia after major ABO-incompatible allogeneic bone marrow transplantation[J]. Bone Marrow Transplanta-tion, 2000, 25(2): 179-184.
[15] 李小力,苏瑞蕊,张霁云,等. ABO血型不相合对异基因造血干细胞移植治疗噬血细胞性淋巴组织细胞增多症后造血重建的影响[J].中国输血杂志,2019, 32(12):1237-1239. LI X L, SU R R, ZHANG J Y, et al. Relevance study of ABO-incompatible and hematopoietic reconstitution after allogeneic hematopoietic stem cell transplantation for he-mophagocytic lymphohistiocytosis [J]. Chinese Journal of Blood Transfusion, 2019, 32(12): 1237-1239.
[16] 鲍立,黄晓军,刘开彦,等. ABO血型不合对异基因造血干细胞移植的影响[J].北京大学学报(医学版),2005,37(2):126-129. BAO L,HUANG X J,LIU K Y,et al, Effect of ABO-incompatibility on allogeneic hematopoietic stem cell transplantation[J]. Journal of Peking University (Health Sciences),2005, 37(2): 126-129.

相似文献/References:

[1]于 帆,楼 爽,黄婷婷,等.基于GEO 数据库筛选胃肠道急性移植物抗宿主病相关基因及其致病机制分析[J].现代检验医学杂志,2023,38(02):13.[doi:10.3969/j.issn.1671-7414.2023.02.003 ]
　YU Fan,LOU Shuang,HUANG Ting-ting,et al.Exploring Gastrointestinal Acute Graft-Versus-Host Disease-Related Genes and Their Pathogenic Mechanisms Based on GEO Database[J].Journal of Modern Laboratory Medicine,2023,38(03):13.[doi:10.3969/j.issn.1671-7414.2023.02.003 ]
[2]石换丽,董慧凤.MDS核型正常患者骨髓DNMT3A，FAT1和IL-7R基因突变对allo-HSCT治疗预后的影响[J].现代检验医学杂志,2025,40(05):82.[doi:10.3969/j.issn.1671-7414.2025.05.016]
　SHI Huanli,DONG Huifeng.Impact of DNMT3A, FAT1, IL-7R Gene Mutations on the Prognosis of Allo-HSCT in MDS Patients with Normal Karyotype[J].Journal of Modern Laboratory Medicine,2025,40(03):82.[doi:10.3969/j.issn.1671-7414.2025.05.016]
[3]王红春,李 梦,孙文利,等.异基因造血干细胞移植患者伏立康唑血药浓度监测不达标风险预测模型建立及验证[J].现代检验医学杂志,2025,40(06):74.[doi:10.3969/j.issn.1671-7414.2025.06.014]
　WANG Hongchun,LI Meng,SUN Wenli,et al.Development and Validation of a Nomogram Prediction Model for Subtherapeutic Voriconazole Concentrations in Allogeneic Hematopoietic Stem Cell Transplantation Recipients[J].Journal of Modern Laboratory Medicine,2025,40(03):74.[doi:10.3969/j.issn.1671-7414.2025.06.014]

备注/Memo

备注/Memo:
作者简介：马峰（1989-），男，硕士，主管检验师，研究方向：临床精准输血与检验，E-mail：893001521@qq.com。
通讯作者：王宝燕（1965-），女，主任医师，研究方向：临床输血相关研究，E-mail：18991232219@189.cn。
更新日期/Last Update: 2026-05-15